Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Eric Lentsch is an Otolaryngologist and a Plastic Surgeon in Charleston, South Carolina. Lentsch has been practicing medicine for over 31 years and is rated as an Elite expert by MediFind in the treatment of Acinic Cell Carcinoma of Salivary Glands. He is also highly rated in 32 other conditions, according to our data. His top areas of expertise are Acinic Cell Carcinoma of Salivary Glands, Salivary Gland Tumors, Throat Cancer, Laryngectomy, and Tissue Biopsy. Lentsch is currently accepting new patients.
Daniel Deschler is an Otolaryngologist and a Plastic Surgeon in Boston, Massachusetts. Deschler has been practicing medicine for over 33 years and is rated as an Elite expert by MediFind in the treatment of Acinic Cell Carcinoma of Salivary Glands. He is also highly rated in 37 other conditions, according to our data. His top areas of expertise are Salivary Gland Tumors, Laryngeal Cancer, Throat Cancer, Laryngectomy, and Tissue Biopsy. Deschler is currently accepting new patients.
David Eisele is an Otolaryngologist in Baltimore, Maryland. Eisele has been practicing medicine for over 41 years and is rated as an Elite expert by MediFind in the treatment of Acinic Cell Carcinoma of Salivary Glands. He is also highly rated in 20 other conditions, according to our data. His top areas of expertise are Salivary Duct Stones, Salivary Gland Tumors, Throat Cancer, Laryngectomy, and Endoscopy. Eisele is currently accepting new patients.
Summary: This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: Epithelial tumors of nasal cavi...
Summary: An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.